Zydus Lifesciences gets USFDA’s final approval for Paliperidone Extended-Release Tablets

10 Oct 2024 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg). Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. 

Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad. The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

957.80 -14.90 (-1.53%)
30-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.20
Dr. Reddys Lab 1377.55
Cipla 1520.65
Lupin 2309.65
Zydus Lifesciences 957.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.